Login / Signup

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma.

Song Lee BakDong-Yeop ShinJunshik HongInho KimYoungil KohJa Min ByunSung-Soo Yoon
Published in: Therapeutic advances in hematology (2021)
BUMEL conditioning deserves attention as the alternative option to HDMEL for newly diagnosed MM patients, even in the era of triplet induction chemotherapy. Specifically, patients achieving very good partial response (VGPR) or better response with triplet induction chemotherapy might benefit the most from BUMEL conditioning. Tailored conditioning regimen, based on patient's response to induction chemotherapy and co-morbidities, can lead to better treatment outcomes.
Keyphrases
  • newly diagnosed
  • multiple myeloma
  • ejection fraction
  • locally advanced
  • prognostic factors
  • squamous cell carcinoma
  • working memory
  • acute lymphoblastic leukemia
  • low dose